Based in the United States, Arvinas is a startup. Brouky records 1 investor associated with the company.
Arvinas is a biopharmaceutical company that develops therapies based on targeted protein degradation (PROTAC) to degrade disease-causing proteins. The company advances small-molecule drugs for oncology and other diseases through its protein degrader platform.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.